Companies

Vanda, Herbalife, Tactile Launch Products; LENZ Adds VIZZ Telehealth

The Tip Desk · November 4, 2026 · 1 min read

Vanda, LENZ, Herbalife and Tactile reported completed launches of NEREUS, a VIZZ telehealth channel, Bioniq and Nimbl.

Vanda Pharmaceuticals Inc. (VNDA) said NEREUS, for the prevention of vomiting induced by motion, became commercially available in the U.S. in May 2026, after approval in December 2025, and that it is continuing the commercial launch as part of current operating plans. The company also said BYSANTI, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia, was approved in February 2026 and is an upcoming commercial launch.

LENZ Therapeutics, Inc. (LENZ) said it announced on July 6, 2026, that VIZZ is now available through a telehealth platform with an integrated online evaluation by independent licensed ECPs, ePharmacy prescription fulfillment, and home delivery, accessible through VIZZ.com. The company said it launched a DTC marketing campaign in January 2026.

HERBALIFE LTD. (HLF) said it launched Bioniq, its next generation of personalized products, as well as new products within Life, in July 2026. It said that during the second quarter of 2026, it launched Bioniq in certain markets, including a subscription-based offering.

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) said Nimbl, its next-generation pneumatic compression platform, received 510(k) clearance in June 2024 and was commercially launched for upper extremity lymphedema in October 2024 and for lower extremity lymphedema in February 2025. The medical technology company said the second generation Entre Plus was released in March 2023.

Vanda said projected pretax income includes significant assumptions related to revenue, which could be affected by the success of the commercial launches of NEREUS and BYSANTI, among other products. LENZ said it expects research and development costs will be de minimis over the remainder of 2026.